Form 4: BMY Executive Hickey Converts RSUs, Sells Shares for Tax

Bristol-Myers Squibb President Benjamin Hickey converted restricted stock units into common shares and subsequently sold a portion for tax obligations.

Summary

• Benjamin Hickey, President of RayzeBio Org. at Bristol-Myers Squibb Company, reported changes in his beneficial ownership.
• On February 1, 2026, Hickey acquired 10,079 shares of Bristol-Myers Squibb common stock through the conversion of Restricted Stock Units (RSUs).
• Concurrently, 3,810 shares were disposed of at a price of $55.05 per share to cover tax obligations related to the RSU vesting.
• Following these transactions, Hickey directly beneficially owns 15,058 shares of common stock.
• The Restricted Stock Units vest annually in three equal installments, with the first installment beginning on February 1, 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral event, reflecting routine executive compensation and tax management rather than a significant positive or negative operational development for Bristol-Myers Squibb.

Positives

• Acquisition of 10,079 shares of common stock through the vesting of Restricted Stock Units, indicating realization of long-term incentive compensation.

Negatives

• Disposal of 3,810 shares to cover tax liabilities, which is a common practice but reduces direct ownership.

Future Outlook

No forward-looking statements or guidance are provided beyond the established vesting schedule for the Restricted Stock Units.

Industry Context

StockSavvy.ai notes that insider transactions like RSU conversions and subsequent tax-related sales are routine events in the pharmaceutical industry, reflecting standard executive compensation practices and not typically indicative of broader industry trends or strategic shifts.

Comparison to Industry Standards

• This type of transaction, where executives convert equity awards and sell a portion to cover taxes, is a standard practice across publicly traded companies, including peers like Pfizer (PFE) or Merck (MRK).
• The specific share price of $55.05 for tax withholding is relevant to BMY's stock performance around the transaction date, but the mechanism itself is globally consistent with equity compensation plans.

Related Party Transactions

• The reported transactions are related party transactions as they involve an executive of Bristol-Myers Squibb Company exercising and selling company stock.

Stakeholder Impact

• Shareholders: Minimal direct impact as these are routine insider transactions related to compensation, not a strategic move affecting company value.
• Employees: Reflects standard executive compensation practices, which may influence employee perception of equity incentives.

Next Steps

• Continued vesting of remaining Restricted Stock Units in annual installments as per the established schedule.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation (RSU vesting and tax-related sales). It does not provide new information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as the filing itself does not present a catalyst for significant price movement or a re-evaluation of the company's fundamentals.

Keywords

Bristol-Myers Squibb, BMY, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Benjamin Hickey, Share Ownership, Tax Withholding